SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.58 | $0 | -$5M |
| 2025 Q4 | -0.31 | $0 | -$6M |
| 2025 Q3 | -0.44 | $0 | -$4M |
| 2025 Q2 | -0.64 | $130,000 | -$4M |
| 2025 Q1 | -0.49 | $0 | -$4M |
| 2024 Q4 | -0.31 | -$14,000 | -$5M |
| 2024 Q3 | 0.16 | $14,000 | -$3M |
| 2024 Q2 | 0.61 | $0 | -$8M |